Companies in #Invasive aspergillosis (azole-resistant)

F2G is a clinical-stage biopharmaceutical company developing olorofim, a first-in-class oral antifungal targeting dihydroorotate dehydrogenase (DHODH), with a novel mechanism of action against difficult-to-treat invasive fungal infections including azole-resistant aspergillosis and rare molds. Headquartered in Manchester, UK; partnered with Shionogi for commercialization in APAC.